Kinstrie, Ross
Horne, Gillian A. http://orcid.org/0000-0001-9741-7352
Morrison, Heather
Irvine, David
Munje, Chinmay
Castañeda, Eduardo Gómez http://orcid.org/0000-0002-7355-2960
Moka, Hothri A.
Dunn, Karen http://orcid.org/0000-0002-6532-970X
Cassels, Jennifer E.
Parry, Narissa
Clarke, Cassie J.
Scott, Mary T.
Clark, Richard E.
Holyoake, Tessa L.
Wheadon, Helen
Copland, Mhairi http://orcid.org/0000-0002-7655-016X
Funding for this research was provided by:
Wellcome Trust (100626/Z/12/Z)
Chief Scientist Office (CAF08/09)
Bloodwise (11017 and 14033)
Kay Kendall Leukaemia Fund (KKL501)
Article History
Received: 8 July 2019
Revised: 17 November 2019
Accepted: 5 December 2019
First Online: 2 January 2020
Change Date: 31 January 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-020-0721-4
Compliance with ethical standards
:
: TLH (sadly passed away), received research funding from Novartis and Bristol-Myers Squibb, was an advisory board member for Novartis and Ariad/Incyte, and received honoraria from Bristol-Myers Squibb, Novartis and Ariad/Incyte. MC has received research funding from Novartis, Bristol-Myers Squibb, Cyclacel and Ariad/Incyte is an advisory board member for Bristol-Myers Squibb, Novartis, Incyte and Pfizer and has received honoraria from Astellas, Bristol-Myers Squibb, Novartis, Ariad/Incyte, Pfizer, Takeda and Celgene. REC, received research funding from Novartis, Bristol-Myers Squibb and Pfizer, was an advisory board member for Novartis, Bristol-Myers Squibb, Jazz pharmaceuticals, Abbvie and Pfizer, and received honoraria from Novartis, Bristol-Myers Squibb, and Pfizer. The other authors declare that they have no conflict of interests.